Skip to main content

Eidos Therapeutics Inc (EIDX) Stock Forecast 2025 - AI Price Prediction & Analysis


Eidos Therapeutics Inc (EIDX) AI Stock Price Forecast & Investment Analysis

Eidos Therapeutics Inc Stock Price Chart and Technical Analysis

Loading Eidos Therapeutics Inc interactive price chart and technical analysis...

Eidos Therapeutics Inc (EIDX) - Comprehensive Stock Analysis & Investment Research

Deep dive into Eidos Therapeutics Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Eidos Therapeutics Inc, including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Eidos Therapeutics Inc: Eidos Therapeutics Inc operates in the Manufacturing sector, establishing it as a mid-cap growth opportunity.

Eidos Therapeutics Inc (Stock Symbol: EIDX) is a leading company in the Manufacturing sector , specifically operating within the Pharmaceutical Preparation Manufacturing industry.

The organization employs approximately 45 professionals worldwide and operates under the strategic leadership of CEO Neil Kumar.

The company has established itself as a growing mid-cap opportunity with strong fundamentals.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Eidos Therapeutics Inc's revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Eidos Therapeutics Inc:

Market Capitalization: $4644 million - Classified as a mid-cap growth stock with balanced risk-reward profile.

Return on Equity (ROE): -70.3% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Eidos Therapeutics Inc stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Eidos Therapeutics Inc: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Eidos Therapeutics Inc stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Eidos Therapeutics Inc's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Eidos Therapeutics Inc: Market positioning analysis based on available financial and operational metrics.

Eidos Therapeutics Inc strategically competes in the highly dynamic Pharmaceutical Preparation Manufacturing marketplace, establishing itself as a promising mid-cap growth opportunity with strong fundamentals and expanding market share .

The company maintains a healthy 100.0% gross margin, indicating strong pricing power and operational efficiency.

Eidos Therapeutics Inc (EIDX) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Eidos Therapeutics Inc stock analysis.

Loading Eidos Therapeutics Inc comprehensive fundamental analysis and insider trading data...

Deep dive into Eidos Therapeutics Inc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Eidos Therapeutics Inc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Eidos Therapeutics Inc: With a P/E ratio of -46.12, the market sees the stock as potentially undervalued.

P/E Ratio -46.12x
P/B Ratio 38.67x
Market Cap $4644M
EPS $-2.65
Book Value/Share $3.16
FCF/Share $-0.68
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Eidos Therapeutics Inc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Eidos Therapeutics Inc: An ROE of -70.3% indicates room for improvement in shareholder value creation.

ROE -70.3%
ROA -59.3%
ROIC -62.9%
Gross Margin 100.0%
Operating Margin -151.6%
Net Margin -141.8%
EBT Margin -141.8%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Eidos Therapeutics Inc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Eidos Therapeutics Inc: A current ratio of 11.10 indicates strong liquidity.

Current Ratio 11.10x
Quick Ratio 10.67x
D/E Ratio 0.17x
Financial Leverage 1.31x
Interest Coverage -44.5x
Working Capital $185M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Eidos Therapeutics Inc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Eidos Therapeutics Inc: Free cash flow of $-86M indicates cash challenges that need attention.

Operating Cash Flow $-85M
Free Cash Flow $-86M
FCF/Sales -119.4%
CapEx/Sales 338.6%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Eidos Therapeutics Inc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Eidos Therapeutics Inc: An asset turnover of 0.15x suggests room for improvement in asset utilization.

Asset Turnover 0.15x
Receivables Turnover 0.8x
Fixed Assets Turnover 0.0x
Days Sales Outstanding 464 days
Payables Period 373 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Eidos Therapeutics Inc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Eidos Therapeutics Inc:

Income Statement ($ Millions)
Operating Income $-100M
Net Income $-101M
R&D Expense $176M
SG&A Expense $67M
Cost of Goods Sold $9M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 95%
Cash & Short-term Investments 91%
Total Liabilities 24%
Accounts Receivable 0%
Dividend & Shareholder Information
Shares Outstanding 38M

Latest Eidos Therapeutics Inc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Eidos Therapeutics Inc (EIDX) stock price and investment outlook.

, source: Benzinga.com

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to ...

Eidos Therapeutics Inc Competitors & Peer Analysis - Manufacturing Sector

Comparative analysis of Eidos Therapeutics Inc against industry peers and competitors in the Manufacturing sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - Eidos Therapeutics Inc Stock Forecast

How accurate are Eidos Therapeutics Inc stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for EIDX predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Eidos Therapeutics Inc stock price forecasts?

Our analysis considers Eidos Therapeutics Inc's financial metrics, Manufacturing sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Eidos Therapeutics Inc a good investment in 2025?

Based on our AI analysis, Eidos Therapeutics Inc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Eidos Therapeutics Inc forecasts updated?

Eidos Therapeutics Inc stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Eidos Therapeutics Inc Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Eidos Therapeutics Inc stock.

My Portfolio

Investment Dashboard

Loading your portfolio...